As compared with the BPH model control rats, the SOD activity of prostates in the AST-treated rats increased in a dose-dependent manner, while the SOD activity of prostates in the 40 mg/kg (p < 0.05) and 80 mg/kg (p < 0.01) AST-treated rats increased significantly. The gene discussed is SOD1; the disease is benign prostatic hyperplasia.